AMY DOYON: Open Payments
NPI 1336818186 · CARMEL, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,170 in 67 payments from 15 companies in 2025. Trend: 2023 $1,955 · 2024 $1,467 · 2025 $1,170
Food & beverage: $1,058Education: $111
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 6 | $212 |
| ABBVIE INC. | 15 | $174 |
| Otsuka America Pharmaceutical, Inc. | 11 | $146 |
| E.R. Squibb & Sons, L.L.C. | 10 | $136 |
| Alkermes, Inc. | 5 | $102 |
| Neurocrine BioSciences, Inc. | 4 | $76 |
| Axsome Therapeutics, Inc. | 3 | $72 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $61 |
| Corium, LLC | 3 | $49 |
| Noven Therapeutics, LLC | 2 | $39 |
Products named: VRAYLAR, COBENFY, ARISTADA, REXULTI, INGREZZA, Auvelity, AUSTEDO XR, CAPLYTA.
Industry payments across IN — which companies pay providers there.
